Combined use of delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis: A systematic review

International Journal of Molecular Sciences

Volumn 18, Issue 2, 2017, Pages

  Migliori, Giovanni Battista ^a   Pontali, Emanuele ^b   Sotgiu, Giovanni ^c   Centis, Rosella ^a   D’Ambrosio, Lia ^a,d   Tiberi, Simon ^e   Tadolini, Marina ^f   Esposito, Susanna ^g,h  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b GALLIERA HOSPITAL   (Italy)

^c UNIVERSITY OF SASSARI   (Italy)

^d Public Health Consulting Group SAGL   (Switzerland)

^e ROYAL LONDON HOSPITAL   (United Kingdom)

^f UNIVERSITY OF BOLOGNA   (Italy)

^g UNIVERSITY OF PERUGIA   (Italy)

^h FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Bedaquiline; Delamanid; Effectiveness; MDR TB; Safety; Tolerability; XDR TB

Indexed keywords

BEDAQUILINE; DELAMANID; NITROIMIDAZOLE; PRETOMANID; VERAPAMIL; NITROIMIDAZOLE DERIVATIVE; OPC-67683; OXAZOLE DERIVATIVE; QUINOLINE DERIVATIVE; TUBERCULOSTATIC AGENT;

DRUG EFFICACY; DRUG SAFETY; DRUG SENSITIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; HUMAN; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; QT PROLONGATION; REVIEW; SCREENING; SPUTUM CULTURE; SPUTUM SMEAR; SYSTEMATIC REVIEW; COMBINATION DRUG THERAPY; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; META ANALYSIS; MICROBIOLOGY; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANTITUBERCULAR AGENTS; DIARYLQUINOLINES; DRUG THERAPY, COMBINATION; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HUMANS; NITROIMIDAZOLES; OXAZOLES; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 85011949875     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms18020341     Document Type: Review

References (49)

1. World Health Organization. Global Tuberculosis Report 2016; WHO/HTM/TB/2016.13; World Health Organization: Geneva, Switzerland, 2016. Available online: http://www.who.int/tb/publications/global_report/en/ (accessed on 30 December 2016).
2. Tiberi, S.; D’Ambrosio, L.; de Lorenzo, S.; Viggiani, P.; Centis, R.; Migliori, G.B. Tuberculosis elimination, patients’ lives and rational use of new drugs: Revisited. Eur. Respir. J. 2016.
3. Falzon, D.; Gandhi, N.; Migliori, G.B.; Sotgiu, G.; Cox, H.S.; Holtz, T.H.; Hollm-Delgado, M.G.; Keshavjee, S.; de Riemer, K.; Centis, R.; et al. Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB. Resistance to fluoroquinolones and second-line injectable drugs: Impact on multidrug-resistant TB outcomes. Eur. Respir. J. 2013, 42, 156–168.
4. Migliori, G.B.; Sotgiu, G.; Gandhi, N.R.; Falzon, D.; de Riemer, K.; Centis, R.; Hollm-Delgado, M.G.; Palmero, D.; Pérez-Guzmán, C.; Vargas, M.H.; et al. Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB. Drug resistance beyond extensively drug-resistant tuberculosis: Individual patient data meta-analysis. Eur. Respir. J. 2013, 42, 169–179.
5. Diel, R.; Rutz, S.; Castell, S.; Schaberg, T. Tuberculosis: Cost of illness in Germany. Eur. Respir. J. 2012, 40, 143–151.
6. Diel, R.; Vandeputte, J.; de Vries, G.; Stillo, J.; Wanlin, M.; Nienhaus, A. Costs of tuberculosis disease in the European Union: A systematic analysis and cost calculation. Eur. Respir. J. 2014, 43, 554–565.
7. World Health Organization. WHO Treatment Guidelines for Drug-Resistant Tuberculosis 2016 Update; WHO/HTM/TB 2016.04; World Health Organization: Geneva, Switzerland, 2016. Available online: http://apps.who.int/iris/bitstream/10665/250125/1/9789241549639-eng.pdf (accessed on 30 December 2016).
8. Migliori, G.B.; de Iaco, G.; Besozzi, G.; Centis, R.; Cirillo, D.M. First tuberculosis cases in Italy resistant to all tested drugs. Euro Surveill. 2007, 12, E070517.1. [PubMed]
9. Caminero, J.A.; Scardigli, A. Classification of antituberculosis drugs: A new proposal based on the most recent evidence. Eur. Respir. J. 2015, 46, 887–893.
10. Sotgiu, G.; Tiberi, S.; D’Ambrosio, L.; Centis, R.; Alffenaar, J.W.; Caminero, J.A.; Arbex, M.A.; Guizado, V.A.; Aleksa, A.; Dore, S.; et al. Faster for less, the new “Shorter” regimen for multidrug-resistant tuberculosis. Eur. Respir. J. 2016, 48, 1503–1507.
11. Falzon, D.; Jaramillo, E.; Schünemann, H.J.; Arentz, M.; Bauer, M.; Bayona, J.; Blanc, L.; Caminero, J.A.; Daley, C.L.; Duncombe, C.; et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur. Respir. J. 2011, 38, 516–528.
12. Tiberi, S.; Scardigli, A.; Centis, R.; D’Ambrosio, L.; Muñoz-Torrico, M.; Salazar-Lezama, M.Á.; Spanevello, A.; Visca, D.; Zumla, A.; Migliori, G.B.; Luna, J.A. Classifying new anti-TB drugs: Rationale and future perspectives. Int. J. Infect. Dis. 2016.
13. Sotgiu, G.; Pontali, E.; Centis, R.; D'Ambrosio, L.; Migliori, G.B. New anti-tuberculosis drugs for special populations: A difficult-to-address issue. Eur. Respir. J. 2016.
14. World Health Organization. The Use of Delamanid in the Treatment of Multidrug-Resistant Tuberculosis: Interim Policy Guidance; WHO/HTM/TB2014.23; World Health Organization: Geneva, Switzerland, 2014. Available online: http://apps.who.int/iris/bitstream/10665/137334/1/WHO_HTM_TB_2014.23_eng.pdf (accessed on 30 December 2016).
15. World Health Organization. The Use of Bedaquiline in the Treatment of Multidrug-Resistant Tuberculosis: Interim Policy Guidance; WHO/HTM/TB/2013.6; World Health Organization: Geneva, Switzerland, 2013. Available online: http://apps.who.int/iris/bitstream/10665/84879/1/9789241505482_eng.pdf (accessed on 30 December 2016).
16. World Health Organization. The Use of Delamanid in the Treatment of Multidrug-Resistant Tuberculosis in Children and Adolescents: Interim Policy Guidance; WHO/HTM/TB/2016.14; World Health Organization: Geneva, Switzerland, 2016. Available online: https://www.ghdonline.org/uploads/Delamanid_guideline_child-adol_Oct16.pdf (accessed on 30 December 2016).
17. Harausz, E.P.; Garcia-Prats, A.; Seddon, J.A.; Schaaf, H.S.; Hesseling, A.; Achar, J.; Bernheimer, J.; Cruz, A.; D’Ambrosio, L.; Detjen, A.; et al. New Drugs, Repurposed Drugs, and Novel Regimens for Children with Multidrug-Resistant Tuberculosis: Practice-Based Recommendations. Am. J. Respir. Crit. Care Med. 2016. Available online: http://www.atsjournals.org/doi/abs/10.1164/rccm.201606-1227CI?url_ver=Z39.88-2003& rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dpubmed& (accessed on 30 December 2016).
18. Pontali, E.; Sotgiu, G.; D’Ambrosio, L.; Centis, R.; Migliori, G.B. Bedaquiline and MDR-TB: A systematic and critical analysis of the evidence. Eur. Respir. J. 2016.
19. Sotgiu, G.; Pontali, E.; Centis, R.; D’Ambrosio, L.; Migliori, G.B. Delamanid (OPC-67683) for treatment of multi-drug-resistant tuberculosis. Expert Rev. Anti Infect. Ther. 2015, 13, 305–315.
20. Tadolini, M.; Garcia-Prats, A.J.; D’Ambrosio, L.; Hewison, C.; Centis, R.; Schaaf, H.S.; Marais, B.J.; Ferreira, H.; Caminero, J.A.; Jonckheere, S.; et al. Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively-drug resistant tuberculosis: Early experiences and challenges. Eur. Respir. J. 2016, 48, 938–943.
21. Esposito, S.; D’Ambrosio, L.; Tadolini, M.; Schaaf, H.S.; Caminero Luna, J.; Marais, B.; Centis, R.; Dara, M.; Matteelli, A.; Blasi, F.; et al. ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: Case study of compassionate delamanid use. Eur. Respir. J. 2014, 44, 811–815.
22. Skripconoka, V.; Danilovits, M.; Pehme, L.; Tomson, T.; Skenders, G.; Kummik, T.; Cirule, A.; Leimane, V.; Kurve, A.; Levina, K.; et al. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur. Respir. J. 2013, 41, 1393–1400.
23. Gler, M.T.; Skripconoka, V.; Sanchez-Garavito, E.; Xiao, H.; Cabrera-Rivero, J.L.; Vargas-Vasquez, D.E.; Gao, M.; Awad, M.; Park, S.K.; Shim, T.S.; et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N. Engl. J. Med. 2012, 366, 2151–2160.
24. Pym, A.S.; Diacon, A.H.; Tang, S.J.; Conradie, F.; Danilovits, M.; Chuchottaworn, C.; Vasilyeva, I.; Andries, K.; Bakare, N.; de Marez, T.; et al. Bedaquiline in the treatment of multi- and extensively drug-resistant tuberculosis. Eur. Respir. J. 2016.
25. Diacon, A.H.; Pym, A.; Grobusch, M.; Patientia, R.; Rustomjee, R.; Liesl, P.S.; Pistorius, C.; Krause, R.; Bogoshi, M.; Churchyard, G.; et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N. Engl. J. Med. 2009, 360, 2397–2405.
26. Diacon, A.H.; Pym, A.; Grobusch, M.P.; de Ios Rios, J.M.; Gotuzzo, E.; Vasilyeva, I.; Leimane, V.; Andries, K.; Bakare, N.; de Marez, T.; et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N. Engl. J. Med. 2014, 371, 723–732.
27. ClinicalTrials.gov. A Service of the U.S. National Institutes of Health. Available online: www.clinicaltrials.gov (accessed on 12 January 2017).
28. Lienhardt, C.; Nahid, P.; Rich, M.L.; Bansbach, C.; Kendall, E.A.; Churchyard, G.; González-Angulo, L.; D'Ambrosio, L.; Migliori, G.B.; Raviglione, M. Target regimen profiles for treatment of tuberculosis: A WHO document. Eur. Respir. J. 2017.
29. Sotgiu, G.; Pontali, E.; Migliori, G.B. Linezolid to treat MDR-/XDR-Tuberculosis: Available evidence and future scenarios. Eur. Respir. J. 2015, 45, 25–29.
30. Villar, M.; Sotgiu, G.; D'Ambrosio, L.; Raymundo, E.; Fernandes, L.; Barbedo, J.; Diogo, N.; Lange, C.; Centis, R.; Migliori, G.B. Linezolid safety, tolerability and efficacy to treat multidrug- and extensively drug-resistant tuberculosis. Eur. Respir. J. 2011, 38, 730–733.
31. De Lorenzo, S.; Centis, R.; D’Ambrosio, L.; Sotgiu, G.; Migliori, G.B. On linezolid efficacy and tolerability. Eur. Respir. J. 2012, 39, 770–772.
32. Sotgiu, G.; Centis, R.; D'Ambrosio, L.; Alffenaar, J.; Anger, H.; Caminero, J.; Castiglia, P.; de Lorenzo, S.; Ferrara, G.; Koh, W.; et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: Systematic review and meta-analysis. Eur. Respir. J. 2012, 40, 1430–1442.
33. Sotgiu, G.; Centis, R.; D’Ambrosio, L.; Spanevello, A.; Migliori, G.B. International Group for the study of Linezolid. Linezolid to treat extensively drug-resistant TB: Retrospective data are confirmed by experimental evidence. Eur. Respir. J. 2013, 42, 288–290.
34. Lee, M.; Lee, J.; Carroll, M.W.; Choi, H.; Min, S.; Song, T.; Via, L.E.; Goldfeder, L.C.; Kang, E.; Jin, B.; et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N. Engl. J. Med. 2012, 367, 1508–1518.
35. Sotgiu, G.; Centis, R.; D’Ambrosio, L.; Castiglia, P.; Migliori, G.B. Low minimal inhibitory concentrations of linezolid against multidrug-resistant tuberculosis strains. Eur. Respir. J. 2015, 45, 287–289.
36. De Lorenzo, S.; Alffenaar, J.W.; Sotgiu, G.; Centis, R.; D’Ambrosio, L.; Tiberi, S.; Bolhuis, M.S.; van Altena, R.; Viggiani, P.; Piana, A.; et al. Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB. Eur. Respir. J. 2013, 41, 1386–1392.
37. Tiberi, S.; Payen, M.C.; Sotgiu, G.; D’Ambrosio, L.; Alarcon Guizado, V.; Alffenaar, J.W.; Abdo Arbex, M.; Caminero, J.A.; Centis, R.; de Lorenzo, S.; et al. Effectiveness and safety of meropenem/ clavulanate-containing regimens in the treatment of multidrug and extensively drug-resistant tuberculosis. Eur. Respir. J. 2016, 47, 1235–1243.
38. Tiberi, S.; Sotgiu, G.; D'Ambrosio, L.; Centis, R.; Abdo Arbex, M.; Alarcon Arrascue, E.; Alffenaar, J.W.; Caminero, J.A.; Gaga, M.; Gualano, G.; et al. Effectiveness and Safety of Imipenem-Clavulanate Added to an Optimized Background Regimen (OBR) versus OBR Control Regimens in the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis. Clin. Infect. Dis. 2016.
39. Tiberi, S.; Sotgiu, G.; D’Ambrosio, L.; Centis, R.; Abdo Arbex, M.; Alarcon Arrascue, E.; Alffenaar, J.W.; Caminero, J.A.; Gaga, M.; Gualano, G.; et al. Comparison of effectiveness and safety of imipenem/ clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of multidrug and extensively drug-resistant tuberculosis. Eur. Respir. J. 2016.
40. Tiberi, S.; D'Ambrosio, L.; de Lorenzo, S.; Viggiani, P.; Centis, R.; Sotgiu, G.; Alffenaar, J.W. Migliori, G.B. Ertapenem in the treatment of multidrug-resistant tuberculosis: First clinical experience. Eur. Respir. J. 2016, 47, 333–336.
41. Matteelli, A.; D'Ambrosio, L.; Centis, R.; Tadolini, M.; Migliori, G.B. Compassionate and optimum use of new tuberculosis drugs. Lancet. Infect. Dis. 2015, 15, 1131–1132.
42. Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G.; The Prisma Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med. 2009, 6, e1000097.
43. Lachâtre, M.; Rioux, C.; Le Dû, D.; Frèchet-Jachym, M.; Veziris, N.; Bouvet, E.; Yazdanpanah, Y. Bedaquiline plus delamanid for XDR tuberculosis. Lancet. Infect. Dis. 2016, 16, 294.
44. Tadolini, M.; Lingtsang, R.D.; Tiberi, S.; Enwerem, M.; D’Ambrosio, L.; Sadutshang, T.D.; Centis R Migliori, G.B. First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline. Eur. Respir. J. 2016, 48, 935–938.
45. Tadolini, M.; Lingtsang, R.D.; Tiberi, S.; Enwerem, M.; D’Ambrosio, L.; Sadutshang, T.D.; Centis, R.; Migliori, G.B. Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid, and clofazimine. Eur. Respir. J. 2016.
46. Wallis, R.S. Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine. Eur. Respir. J. 2016.
47. Bonnet, M.; Bastard, M.; du Cros, P.; Khamraev, A.; Kimenye, K.; Khurkhumal, S.; Hayrapetyan, A.; Themba, D.; Telnov, A.; Sanchez-Padilla, E.; Hewison, C.; Varaine, F. Identification of patients who could benefit from bedaquiline or delamanid: A multisite MDR-TB cohort study. Int. J. Tuberc. Lung Dis. 2016, 20, 177–186.
48. Ferlazzo, G. Dlm-Bdq combination: Programmatic aspects and preliminary results of patients receiving Dlm and Bdq combination in MSFNTP projects. Satellite session (SS) 02. Pushing the boundaries: Use of new TB drugs. In Proceedings of the 47th Union World Conference on Lung Health, Liverpool, UK, 26–29 October 2016.
49. Conradie, F.; Diacon, A.; Mendel, C.; Everitt, D.; van Niekerk, C.; Howell, P.; Spigelman, M. Interim results of nix-TB clinical study of pretomanid, bedaquiline and linezolid for treatment of XDR and treatment intolerant/failed MDR-TB. In Proceedings of the 47th Union World Conference on Lung Health, Liverpool, UK, 26–29 October 2016.